Monocarboxylate transporter 2 (MCT2) as putative biomarker in prostate cancer

Abstract

We provided evidence for the presence of MCT2 in prostate cancer, selectively labeling malignant glands. Importantly, assessment of MCT2 together with AMACR, along with the negative markers, highly increases the accuracy in prostate cancer diagnosis.